Last updated at 15 Jun 2025 03:05 AM
Director
DIN: 08858197
Bhaskar Babu Koyyalamudi is currently associated with 2 companies in various capacities such as Director and Individual Promoter. They serve as a Director at ABVITA PHARMACEUTICALS PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08858197.Bhaskar Babu Koyyalamudi is currently involved in 2 different roles. Their most recent position is with TAIRIS GLOBAL PRIVATE LIMITED as a Director. The first company Bhaskar Babu Koyyalamudi was appointed to as a director was ABVITA PHARMACEUTICALS PRIVATE LIMITED. Bhaskar Babu Koyyalamudi is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Bhaskar Babu Koyyalamudi is currently associated with 2 companies in various capacities such as Director and Individual Promoter. They serve as a Director at ABVITA PHARMACEUTICALS PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08858197.Bhaskar Babu Koyyalamudi is currently involved in 2 different roles. Their most recent position is with TAIRIS GLOBAL PRIVATE LIMITED as a Director. The first company Bhaskar Babu Koyyalamudi was appointed to as a director was ABVITA PHARMACEUTICALS PRIVATE LIMITED. Bhaskar Babu Koyyalamudi is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
3
Male
India
Gain instant access to verified contact details.
Current Companies (2)
Current LLPs (0)
Past Companies (0)
1y 1m 7 Months Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| ABVITA PHARMACEUTICALS PRIVATE LIMITED | Director | 01-Sep-2020 |
| ABVITA PHARMACEUTICALS PRIVATE LIMITED | Individual Promoter | 01-Sep-2020 |
| TAIRIS GLOBAL PRIVATE LIMITED | Director | 14-Jun-2025 |